AUTL vs NBIX · rev $71.9M vs P/E 45, rev $1.77B
Autolus Therapeutics Ltd (AUTL) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Autolus Therapeutics Ltd (AUTL) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported AUTL revenue for 2026-06-30 was $71.9M. Net income was -$110.7M. AUTL currently screens at market cap $614.8M.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
AUTL currently screens at market cap $614.8M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the AUTL and NBIX stock pages for the full models.
Not investment advice.